Lv42
710 积分 2023-09-24 加入
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma
1个月前
已完结
RECIST 1.1—Update and clarification: From the RECIST committee
1个月前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
1个月前
已完结
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
1个月前
已完结
Comparing PD‐L1 and PD‐1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single‐center, real‐world study
1个月前
已完结
Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
2个月前
已完结
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
2个月前
已完结
Advances in immunotherapy for hepatocellular carcinoma
2个月前
已完结
皖公网安备34019202002308
